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Objective To evaluate the in vitro activity of quinupristin/dalfopristin (Q/D), a streptogramin
combination, in comparisonwith ¢ve antibiotics against worldwide clinical isolates of staphylococci.
Methods Amulticenter in vitro studywas performed using the E test during a period of 3months (April
to June) in1997 on fresh, clinically signi¢cant, non repetitive strains of staphylococci frompatients
hospitalized in 23 di¡erent hospitals in18 countries tested.
Results Atotal of 2132 staphylococcal isolates includingmethicillin resistant (MR),methicillin
susceptible (MS) S. aureus (1003MS, 462MR), S. epidermidis (169MS, 251MR), S. haemolyticus (28MS, 46
MR), S. hominis (28MS,16MR), and coagulase negative staphylococci (86MS, 43MR)were analyzed.
Q/Dwas highly active against all species tested.MIC90 (mg/L) ranged from 0.5 to 2 depending on the
species. Strains hadMICR1mg/L in 97.6%. For S. aureus, S. epidermidis, S. hominis and other coagulase-
negative staphylococci no di¡erences inMIC90 were observed forMS orMR.One dilution di¡erencewas
observed for S. haemolyticus, which overall was the less susceptible species. Erythromycin resistancewas
observed among 57^87% of MR-strains andwas lower amongMS-strains (18^56%). Erythromycin
resistance had no or little in£uence onMIC of Q/D. In comparison tovancomycin, Q/Dwas two to four
times more active.
Conclusions The streptogramin combinationQ/D showed an excellent in vitro activity against all
staphylococcal species tested regardless of the resistance pattern to other drug classes, particularly resistance
tomethicillin. Q/Dwas two to four timesmore active thanvancomycin andMICvalues varied from 0.5^2
according to the species.The synergyof Q/Dwaswell conserved inmacrolide-resistant strains.
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I N T R O D U C T I O N
The incidence of infections caused by multiresistant Gram-
positive bacteria is increasing, despite advances in antibacterial
therapy over the last 20 years. In particular, this threat is repre-
sented by staphylococcal strains that are frequently resistant to
most currently available antibiotics.
The recent detection of strains of Staphylococcus aureus with
reduced susceptibility to vancomycin has caused great con-
cern, since vancomycin is the agent of choice for the treatment
of infections caused bymultiresistant staphylococci [1]. There-
fore, new antibacterial agents are currently needed to treat
severe infections.
Quinupristin/dalfopristin is a combination of quinupristin
(30%) and dalfopristin (70%), which are semisynthetic water-
soluble derivatives of pristinamycin IA and pristinamycin IIA,
respectively, making quinupristin/dalfopristin the ¢rst strep-
togramin antibiotic suitable for parenteral use [2].
Quinupristin/dalfopristin has an uncommon in vitro spec-
trum of activity which includes most multiresistant Gram-
positive aerobes, Gram-positive anaerobes and intracellular
bacteria [3,4]. Another noteworthy characteristic of quinu-
pristin/dalfopristin is the strong synergistic activity of its two
components, which is observed even on strains that are resis-
tant to either quinupristin or dalfopristin [5,6].
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Shortly before its introduction into clinical practice, a mul-
ticenter study encompassing 23 hospitals in 18 countries was
performed to assess the in vitro activity of quinupristin/dalfo-
pristin on 2132 staphylococcal clinical isolates in comparison
with ¢ve antimicrobial agents frequently used to treat severe
staphylococcal infections.
M A T ER I A L S A N D ME T H O D S
Between April and June 1997, each hospital laboratory was
requested to collect consecutive, non-repetitive strains of sta-
phylococci. The strains were obtained from hospitalized
patients andwere identi¢ed on the basis of tests recommended
in theManual of Clinical Microbiology [7]. Each participant had
to test less than 50% of coagulase-negative staphylococci
(CNS). Clinically signi¢cant strains had to be isolated from
blood, cerebrospinal £uid, upper and lower respiratory tract,
urinary tract, skin and soft tissue, bone and joint, intra-
abdominal infections and foreign bodies.
The following organismswere included for quality control:
S. aureus UA118, S. aureus UA238 and S. hemolyticus UA238
(Institut Pasteur, Paris, France).These strains were tested every
week.
Minimal inhibitory concentrations (MICs) of quinupris-
tin/dalfopristin, erythromycin, clindamycin, cipro£oxacin,
gentamicin and vancomycin were determined by the E-test
method (AB Biodisk, Solna, Sweden) on Mueller^Hinton
agar according to the manufacturer's recommendations. Sus-
ceptibility to oxacillin was determined according to NCCLS
recommendations by performing the screening test with agar
plates containing 6mg/L oxacillin and 4% NaCl or by the
disk method (1-mg oxacillin disks, incubated at 30 C for 24 h)
[8].
Breakpoints were as proposed by the NCCLS [8]. For qui-
nupristin/dalfopristin, the breakpoints were 1 and 4mg/L, as
recommended byTenover and Baker [9].
Sterile stock solutions of the antibiotics and E-test strips
were stored at ^ 20 C.
R ES U L T S
The origins of the strains (per country) and their resistance to
methicillin are summarized in Table1. Overall, 38% of the
strains were resistant tomethicillin.
The percentages of species collected were as follows: S. aur-
eus 68%, S. epidermidis 20%, S. hemolyticus 3%, S. hominis 2%,
S. saprophyticus 1%, S. warneri 1%, S. xylosus 1%, S. lugdunensis
1%, other CNS 3%.
Strains were isolated from skin and soft tissues (38%),
blood (13%), lower respiratory tract (12%), urinary tract
(10%), catheter (6%), abdominal (5%), upper respiratory tract
(3%) and bone and joint (3%) infections, biopsy (2%), for-
eign bodies (2%), central nervous system (1%) and other
sources (5%).
Table 1 Origin of strains and their methicillin susceptibility
S. aureus S. epidermidis S. haemolyticus S. hominis CNS
Country MS MR MS MR MS MR MS MR MS MR
Algeria 48 3 27 13 0 0 0 1 6 2
Austria 31 37 10 17 3 1 1 1 0 0
Czech Republic 67 2 4 18 0 1 2 4 2 0
Slovak Republic 36 8 10 12 7 4 6 1 9 7
Egypt 26 14 7 3 3 3 2 1 8 2
Greece 93 76 17 42 2 9 2 2 3 1
Hungary 49 1 10 13 4 8 6 5 3 1
India 17 82 0 0 0 0 0 0 0 0
Israel 31 30 6 8 0 1 0 0 10 11
Lebanon 35 16 18 15 4 4 3 0 3 1
Morocco 68 20 2 3 0 2 3 1 1 0
Pakistan 25 15 6 2 1 2 0 0 7 5
Russia 8 34 7 43 0 2 0 0 1 4
Saudi Arabia 15 30 15 16 0 0 0 0 0 0
South Africa 134 50 1 7 1 1 0 0 5 1
Switzerland 223 14 19 30 1 1 2 0 7 2
Tunisia 51 6 7 4 0 1 0 0 11 3
Turkey 46 24 3 5 2 6 1 0 10 3
Total 1003 462 169 251 28 46 28 16 86 43
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Table 2 In vitro susceptibility (mg/L) of Staphylococcus spp. to quinupristin/dalfopristin (Q/D) and other antimicrobial agents
Species (no of isolates) Agent MIC Range MIC50 MIC90 Susceptible (%)
c
S. aureus (MSa) (1003) Q/D 0.06±4 0.5 1 99
Vancomycin 0.12±4 1 2 100
Erythromycin 0.03 to >256 0.25 4 82
Clindamycin 0.12 to >256 0.12 0.25 97
Cipro¯oxacin 0.06 to >256 0.25 0.5 95
Gentamicin 0.015 to >256 0.5 2 96
S. aureus (MRb) (462) Q/D 0.12±8 0.5 1 95
Vancomycin 0.25±4 1 2 100
Erythromycin 0.03 to >256 > 256 > 256 25
Clindamycin 0.03 to >256 0.25 > 256 58
Cipro¯oxacin 0.06 to >256 > 256 > 256 35
Gentamicin 0.03 to >256 128 > 256 23
S. epidermidis (MS) (169) Q/D 0.12±2 0.25 0.5 99
Vancomycin 0.12±4 2 4 100
Erythromycin 0.03 to >256 0.5 > 256 64
Clindamycin 0.015 to >256 0.12 0.5 91
Cipro¯oxacin 0.06 to >256 0.25 0.5 90
Gentamicin 0.015 to >256 0.12 4 90
S. epidermidis (MR) (251) Q/D 0.12±2 0.25 0.5 98
Vancomycin 0.25±6 2 2 99
Erythromycin 0.03 to >256 > 256 > 256 23
Clindamycin 0.015 to >256 4 > 256 49
Cipro¯oxacin 0.06 to >256 1 > 256 50
Gentamicin 0.015 to >256 32 > 256 31
S. hemolyticus (MS) (28) Q/D 0.12±2 0.5 1 93
Vancomycin 0.25±4 1 2 100
Erythromycin 0.06 to >256 1 > 256 44
Clindamycin 0.03±4 0.12 1 88
Cipro¯oxacin 0.12 to >256 0.25 > 256 75
Gentamicin 0.03±128 0.12 16 86
S. hemolyticus (MR) (46) Q/D 0.25±4 0.5 2 85
Vancomycin 0.5±4 2 4 100
Erythromycin 0.12 to >256 128 > 256 13
Clindamycin 0.06 to >256 0.5 > 256 53
Cipro¯oxacin 0.06 to >256 > 256 > 256 46
Gentamicin 0.03 to >256 32 > 256 31
S. hominis (MS) (28) Q/D 0.25±1 0.25 0.5 100
Vancomycin 0.5±2 2 2 100
Erythromycin 0.06 to >256 1 > 256 46
Clindamycin 0.03 to >256 0.25 > 256 88
Cipro¯oxacin 0.03 to >256 0.25 > 256 86
Gentamicin 0.03 to >256 0.12 32 86
S. hominis (MR) (16) Q/D 0.12±0.5 0.25 0.5 100
Vancomycin 0.5±4 1 2 100
Erythromycin 0.12 to >256 32 > 256 31
Clindamycin 0.03 to >256 0.25 > 256 60
Cipro¯oxacin 0.06 to >256 0.5 > 256 56
Gentamicin 0.06 to >256 4 > 256 50
Other CNS (MS) (86) Q/D 0.12±2 0.5 1 98
Vancomycin 0.25±4 1 2 100
Erythromycin 0.03 to >256 0.5 > 256 62
Clindamycin 0.03 to >256 0.12 1 89
Cipro¯oxacin 0.03 to >256 0.25 0.5 95
Gentamicin 0.015 to >256 0.12 1 93
Other CNS (MR) (43) Q/D 0.25 to >32 0.25 1 95
Vancomycin 0.25±4 1 2 100
Erythromycin 0.03 to >256 8 > 256 43
Clindamycin 0.03 to >256 0.25 > 256 70
Cipro¯oxacin 0.06 to >256 1 > 256 57
Gentamicin 0.015 to >256 1 > 256 57
aMS, methicillin susceptible; bMR, methicillin resistant; cQ/D-susceptible strains MIC R 1 mg/L, Q/D-resistant strains MIC r 4 mg/L, according
to provisional interpretative criteria for Q/D susceptibility tests ([9]).
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The MIC ranges, MIC50, MIC90 (mg/L) and percentages
of susceptible strains are indicated in Table 2. Quinupristin/
dalfopristin was highly active against all species tested; 99%
and 95% of methicillin-susceptible and methicillin-resistant
S. aureus strains, respectively, were susceptible to the drug; 85^
100% of the isolates of the other species were also suscepti-
ble.
MIC90 (mg/L) ranged from 0.5 to 2, depending on the spe-
cies. For four species (see Table 2), no di¡erences in MIC90
were observed formethicillin-susceptible or -resistant isolates.
One dilution di¡erence was observed for S. hemolyticus,
which, overall, was the least susceptible species. This species
was also the least susceptible to erythromycin. Erythromycin
resistance was observed among 57^87% of methicillin-resis-
tant strains and was lower among methicillin-susceptible iso-
lates (18^56%). A high percentage of resistance to clindamycin
(MIC> 256mg/L) among methicillin-resistant strains was
also observed.
Vancomycinwas active against all but two strains of methi-
cillin-resistant S. epidermidis. Identi¢cation and MICs of these
two strains could not be retested by the Central Laboratory
(Geneva), and these results were therefore excluded from
Table 2.
Quality control tests indicated that the results were homo-
geneous between the di¡erent centers.
D I S C U S S IO N
Despite advances in antibacterial therapy, the incidence of
infections caused by multiresistant Gram-positive bacteria is
increasing [10,11].With the appearance of several species resis-
tant to glycopeptides, including S. aureus isolates, the need for
alternative therapy becomes evenmore urgent [1,12].
Quinupristin/dalfopristin, an injectable streptogramin
antibiotic, is a new agent which possesses in vitro activity
against Gram-positive pathogens [3,13]. The potential of this
activity has been con¢rmed in humans by many clinical stu-
dies [14]. Multicenter studies have revealed that quinupristin/
dalfopristin activity was similar within 1or 2 dilutions in Eur-
ope, North America, Asia and Africa.
The data reported here con¢rm this observation, with
strains isolated from 18 European, Asian and African coun-
tries: 97.6% of these strains have an MICR1mg/L, and the
MIC90 wasR1mg/L for the 2132 isolates tested (including
38% of methicillin-resistant strains). In this study, quinupris-
tin/dalfopristin activity was homogeneous irrespective of the
species, except for methicillin-resistant S. hemolyticus, which
was more resistant (MIC90 2mg/L; % susceptible 85%). Such
a tendency has not been previously reported [15].
Susceptibility or resistance to macrolides and lincosamides
have no or little e¡ects on quinupristin/dalfopristin MICs:
there was no or one dilution di¡erence in MICs of the two
phenotypes; di¡erences in the percentage of susceptible strains
ranged from 0% to 8% (S. hemolyticus being the most
a¡ected).
This con¢rms the fact that synergy between quinupristin
and dalfopristin, as well as the activity of the combination, are
well conserved in macrolide- and quinupristin (a macrolide-
like structure)-resistant strains [5,6]. The molecular mechan-
isms of action of quinupristin and dalfopristin may explain
this observation [16,17]. However, the bactericidal activity
may be decreased against some strains displaying the MLSB
constitutive phenotype [18].
Another interesting point is the fact that quinupristin/dal-
fopristin was as active in France and in the USA, where oral
streptogramins (pristinamycin, virginiamycin) have been used
over the past 30 years in humans and animals, as in countries
where these two drugs were not available. Nevertheless, the
periodic isolation of a few hospital resistant clones [17,19] indi-
cates that quinupristin/dalfopristin use should be carefully
monitored in order to preserve activity of the drug.
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